Regulatory & Legal

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

Independent firm FPA is nominated for a top Morningstar award alongside PIMCO and Vanguard, highlighting its rare focus on investor returns over asset size.

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

After a transformative year, PRF Technologies ditches its old model for a bold new strategy in AI-driven solar analytics and advanced ocular healthcare.

Hyundai, Genesis, and Kia secured 16 top safety ratings, including 15 TSP+ awards, showcasing their leadership under the IIHS's toughest criteria yet.

Hyundai earned a top innovation award for its aggressive EV strategy, new IONIQ 9 SUV, and massive U.S. manufacturing investment. Here's how it happened.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

RenX Enterprises touts massive growth after a reverse split, but a closer look reveals dilution risks, a heavy debt load, and a paid promotional campaign.

A major investment aims to develop biomarkers for TAND, the neuropsychiatric challenges affecting most with TSC, offering new hope for families.

Benefits giant Alight is on the clock to save its NYSE listing after its stock price collapsed. Can a risky reverse stock split fix its deeper issues?

A landmark partnership aims to tap Australia's vast Beetaloo gas reserves for domestic use and LNG export, igniting both economic hopes and fierce opposition.

Neutech Group builds on its education, healthcare, and wellness strategy, but a closer look at its 2025 financials reveals a more complex picture.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

The SFC-licensed platform now offers the most compliant tokenized securities in Hong Kong, bridging institutional capital with on-chain finance.

From Taiwan to the world, Gogoro's battery swapping network is reshaping urban transport. Can its proven model solve Asia's mobility and pollution woes?

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

Keurig Dr Pepper's upcoming Q1 results are more than just numbers; they're the first look at a company on the brink of a massive transformation.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

An inmate's escape by allegedly impersonating another has triggered a national investigation, exposing critical flaws in Canada's correctional system.

Cambridge's acquisition of an $800M firm highlights a growing industry trend of broker-dealers becoming buyers to solve the advisor succession crisis.